ArticleEBioMedicine2017
Microbiome Remodeling via the Montmorillonite Adsorption-Excretion Axis Prevents Obesity-related Metabolic Disorders.
Article in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 80 citations in OpenAlex.
- Calcium montmorillonite clay: a clinically oriented narrative review of emerging perioperative and supportive applications.Annals of translational medicine · 2026Review
- Konjac Glucomannan-Montmorillonite Hybrids as a Gut-Targeted Therapy for Addressing Diet-Induced Obesity in Mice.Nutrients · 2026Article
- Review
- Nanocarrier-enabled delivery of natural antiobesity agents.Nanomedicine (London, England) · 2025Review
- Gallic acid prevents obesity in mice on a high-fat diet via the gut microbiota-adipose tissue axis.Current research in food science · 2025Article
- Article
- Article
- Article
- The Impact of the Gut Microbiome, Environment, and Diet in Early-Onset Colorectal Cancer Development.Cancers · 2024Review
- Targeted Nano-Based Systems for the Anti-Obesity Agent's Delivery.Advances in experimental medicine and biology · 2024Review
- Composite Hydrogels with Included Solid-State Nanoparticles Bearing Anticancer Chemotherapeutics.Gels (Basel, Switzerland) · 2023Review
- Modulation of Fat Deposition-Gut Interactions in Obese Mice by Administrating with Nobiletin.Genes · 2023Article
- Sulforaphane Ameliorates Nonalcoholic Fatty Liver Disease Induced by High-Fat and High-Fructose Diet via LPS/TLR4 in the Gut-Liver Axis.Nutrients · 2023Article
- Compound dark tea ameliorates obesity and hepatic steatosis and modulates the gut microbiota in mice.Frontiers in nutrition · 2023Article
- Depletion of Gut Microbiota Inhibits Hepatic Lipid Accumulation in High-Fat Diet-Fed Mice.International journal of molecular sciences · 2022Article
- Article
- Diabetes and gut microbiota.World journal of diabetes · 2021Review
- Melatonin Attenuates Dextran Sodium Sulfate Induced Colitis in Obese Mice.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and its related metabolic disorders are closely correlated with gut dysbiosis. Montmorillonite is a common medicine used to treat diarrhea. We have previously found that dietary lipid adsorbent-montmorillonite (DLA-M) has an unexpected role in preventing obesity. The aim of this study was to further investigate whether DLA-M regulates intestinal absorption and gut microbiota to prevent obesity-related metabolic disorders. Here, we show that DLA-M absorbs free fatty acids (FFA) and endotoxins in vitro and in vivo. Moreover, the combination of fluorescent tracer technique and polarized light microscopy showed that DLA-M crystals immobilized BODIPY® FL C16 and FITC-LPS, respectively, in the digestive tract in situ. HFD-fed mice treated with DLA-M showed mild changes in the composition of the gut microbiota, particularly increases in short-chain fatty acids (SCFA)-producing Blautia bacteria and decreases in endotoxin-producing Desulfovibrio bacteria, these changes were positively correlated with obesity and inflammation. Our results indicated that DLA-M immobilizes FFA and endotoxins in the digestive tract via the adsorption-excretion axis and DLA-M may potentially be used as a prebiotic to prevent intestinal dysbiosis and obesity-associated metabolic disorders in obese individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.